翻訳中 — お使いの言語版を準備している間、このコンテンツは英語で表示されています。

ディスカッションに戻る

ディスカッションを保存

サインインして保存して更新を取得してください。

When AI designs a drug, who gets the credit?

Healthcare

グローバル

August 22, 2026に開始

When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think…

ソース記事

When AI designs a drug, who gets the credit?

MIT Technology Review (United States) | Aug 21, 2026

主張を追加分析 0/5

並び替え：

Need to find a specific claim? Search all statements.

🗳️ Join the conversation

10 投票すべき主張 • Your perspective shapes the analysis

📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement

Participants 0/7

Statements (10+ recommended) 10/10

Total Votes 0/20

💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 投稿者： admin • Aug 22, 2026

AI's role in drug design should be recognized as transformative, warranting its inclusion in authorship and credit.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

Attributing credit to AI undermines the role of human expertise in drug development.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

The pharmaceutical industry must establish clear guidelines for attributing credit to AI and human contributors in drug discovery.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

The potential of AI in drug discovery should be acknowledged in scientific publications to reflect its contributions accurately.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

Collaborative efforts between AI and human researchers should be emphasized to foster innovation in drug development.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

AI should be credited as a co-inventor in drug discovery when it significantly contributes to the design process.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

Transparency in the drug discovery process is essential to determine how credit is assigned between AI and human researchers.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

AI systems that design drugs should be considered tools, not inventors, maintaining human primacy in the innovation process.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

Public trust in AI-generated drug discoveries hinges on clear attribution of credit and accountability.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

CLAIM 投稿者： admin • Aug 22, 2026

Only human scientists should receive credit for drug discoveries, regardless of AI's involvement in the process.

翻訳準備中

💬 ディスカッションを見る

Be first to respond

Vote to see results

💡 How This Works

• Add Statements: Post claims or questions (10-500 characters)
• Vote: Agree, Disagree, or Unsure on each statement
• Respond: Add detailed pro/con responses with evidence
• Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.